Vasopressin analog that acts only on the receptor that constricts blood vessels. Studied to raise blood pressure in septic shock, without success.
Regulatory status
Not approved
Family
Selective vasopressin V1a receptor agonist
Scientific evidence
High
Number of findings
1
Where it acts
Heart and blood · Immunity and defense
Also known as
selepressin, FE 202158
Regulatory status
FDA (US): Not approved (phase 2b/3 SEPSIS-ACT stopped for futility)
EMA (EU): Not approved
Dose
There is no established dose in humans.
Safety
In the trial, arrhythmias (28% vs 25%) and cardiac, intestinal, or peripheral ischemia in proportions similar to placebo. ICU research only.
Effect by goal · level of evidence
Septic shock: days free of ventilator and vasopressors
no clear effectHighRCT (AA)in people
No benefit
SEPSIS-ACT trial with 828 patients: 15.0 vs 14.5 days free of ventilator and vasopressors, and 90-day mortality of 40.6% vs 39.4%. Stopped for futility.
Activates only the V1a receptor, which narrows blood vessels and raises blood pressure. It was thought that, by not acting on other vasopressin receptors, it would reduce fluid leakage and the unwanted effects of norepinephrine.
What the evidence says
In people
Septic shock: days free of ventilator and vasopressors. SEPSIS-ACT trial with 828 patients: 15.0 vs 14.5 days free of ventilator and vasopressors, and 90-day mortality of 40.6% vs 39.4%. It was stopped for futility. PubMed 31577035